AstraZeneca Reports P-III (CALYPSO) Trial Data of Eneboparatide for Chronic Hypoparathyroidism (HypoPT)
Shots:
- AstraZeneca has reported global P-III (CALYPSO) trial data assessing eneboparatide vs PBO in chronic hypoparathyroidism adults (n=202) who received SoC (active vit D & oral Ca supplementation) for 24wks., followed by an ongoing long-term extension period until 52wks.
- Trial met its 1EP, with higher number of pts achieving albumin-adjusted serum calcium within normal range & independence from SoC after 24wks; full data to be analysed at 52wks. Results to be shared with global health authorities & highlighted at future meetings
- Eneboparatide (AZP-3601) selectively binds to a specific PTH receptor 1 conformation to restore PTH function & manage symptoms of HypoPT, while preserving kidney function & bone health
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports the EC’s Approval of Imfinzi to Treat Limited-Stage Small Cell Lung Cancer (LS-SCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
